Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Bio-Rad Laboratories, Inc. is a global life science research and clinical diagnostics company that develops, manufactures, and markets analytical instruments, reagents, consumables, and software. The company operates primarily within the life science research and clinical diagnostics industries, serving academic institutions, biotechnology and pharmaceutical companies, hospitals, reference laboratories, and government and industrial customers. Its products are used for analyzing DNA, RNA, proteins, and cells, as well as for disease detection, monitoring, and quality control.
The company’s primary revenue drivers are its Life Science and Clinical Diagnostics segments, with recurring revenue generated from reagents, consumables, and assay kits complementing instrument sales. Bio-Rad is positioned as a premium provider known for analytical accuracy, regulatory compliance, and long-term customer relationships. Founded in 1952 by David Schwartz and Alice Schwartz, Bio-Rad began as a small diagnostics company and expanded over decades through internal innovation and acquisitions into a diversified global supplier of research and clinical testing solutions.
Business Operations
Bio-Rad operates through two reportable business segments: Life Science and Clinical Diagnostics. The Life Science segment provides instruments, reagents, and software for biological research, including products for genomics, proteomics, cell biology, and food and environmental testing. The Clinical Diagnostics segment develops and supplies diagnostic systems, test kits, and quality controls used in clinical laboratories for blood typing, diabetes monitoring, infectious disease testing, and autoimmune diagnostics.
The company generates revenue through direct sales, distributors, and long-term supply agreements across both segments, with a strong emphasis on consumables that create recurring demand. Bio-Rad maintains manufacturing, R&D, and distribution operations globally and controls proprietary technologies related to droplet digital PCR, quality controls, and immunohematology. It operates through numerous wholly owned subsidiaries and maintains strategic minority investments, most notably its equity stake in Sartorius AG, which is accounted for as an investment rather than an operating subsidiary.
Strategic Position & Investments
Bio-Rad’s strategic direction focuses on expanding high-margin consumables, strengthening its position in molecular diagnostics, and leveraging advanced analytical technologies such as droplet digital PCR and multiplex testing. The company continues to invest in research and development to enhance automation, data integration, and regulatory-compliant diagnostics for clinical and regulated laboratory environments. Growth initiatives include expanding test menus, increasing penetration in emerging markets, and deepening relationships with pharmaceutical and biotechnology customers.
A significant element of Bio-Rad’s strategic profile is its long-standing investment in Sartorius AG, a global provider of bioprocessing and laboratory technologies, which provides financial returns and strategic insight into adjacent life science markets. Bio-Rad has also completed selective acquisitions over time to expand diagnostic assay portfolios and technology platforms; however, no single recent acquisition dominates its revenue base based on available public disclosures.
Geographic Footprint
Bio-Rad is headquartered in North America in Hercules, California, and operates in more than 35 countries worldwide. Its largest markets include the United States, Europe, and Asia-Pacific, with meaningful operations across Germany, France, China, and Japan. The company maintains manufacturing and R&D facilities in multiple regions to support regulatory requirements and regional customer needs.
International markets account for a substantial portion of Bio-Rad’s revenue, reflecting its broad global distribution network and localized sales organizations. The company’s geographic diversification helps balance demand across academic research cycles, healthcare spending patterns, and government funding environments in different regions.
Leadership & Governance
Bio-Rad is led by a management team with deep tenure in life sciences, diagnostics, and regulated healthcare markets. The company maintains a governance structure that emphasizes long-term value creation, disciplined capital allocation, and scientific integrity, with strategic oversight influenced by its history as a founder-led organization and its ongoing investment holdings.
Key executives include:
- Norman Schwartz – President and Chief Executive Officer
- Ilan Daskal – Executive Vice President and Chief Financial Officer
- Michael Crowley – Executive Vice President, Life Science Group
- Gary Loew – Executive Vice President, Clinical Diagnostics Group
- Clifford J. Burroughs – Executive Vice President, Global Operations
Leadership philosophy centers on sustained innovation, operational excellence, and maintaining strong regulatory and quality standards across global operations, consistent with the company’s long-standing presence in clinical and research markets.